The drug is designed to improve progression-free survival. The approval was based on demonstration of improved progression-free survival in a multicenter, international, randomized, double-blind, placebo-controlled study.
Safety data was also evaluated. The most commonly reported adverse reactions in lanreotide-treated patients were abdominal pain, musculoskeletal pain, vomiting, headache, injection site reaction, among others.
More articles on gastroenterology:
Dr. Sonia Kupfer meets with National Institute of Diabetes and Digestive and Kidney Diseases
Newman Regional Health to acquire $345k endoscopy system
New EndoChoice slim scope, US Endoscopy distribution agreement & more – 6 GI/endoscopy company key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
